Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Cryptosporidiosis - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 32 | Code: MRS - 18544


Global Markets Directs, Cryptosporidiosis Pipeline Review, H2 2014, provides an overview of the Cryptosporidiosiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cryptosporidiosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cryptosporidiosis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Cryptosporidiosis
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Cryptosporidiosis and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Cryptosporidiosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Cryptosporidiosis pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Cryptosporidiosis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Cryptosporidiosis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content 

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Cryptosporidiosis Overview 6
Therapeutics Development 7
Pipeline Products for Cryptosporidiosis - Overview 7
Pipeline Products for Cryptosporidiosis - Comparative Analysis 8
Cryptosporidiosis - Therapeutics under Development by Companies 9
Cryptosporidiosis - Therapeutics under Investigation by Universities/Institutes 10
Cryptosporidiosis - Pipeline Products Glance 11
Early Stage Products 11
Cryptosporidiosis - Products under Development by Companies 12
Cryptosporidiosis - Products under Investigation by Universities/Institutes 13
Cryptosporidiosis - Companies Involved in Therapeutics Development 14
ioGenetics, LLC 14
Cryptosporidiosis - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Drug Profiles 23
cryptosporidiosis vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
cryptosporidiosis vaccine (divalent) - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DBAF-201 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
P-131 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules to Inhibit IMPDH for Cryptosporidiosis - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cryptosporidiosis - Dormant Projects 30

Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables

Number of Products under Development for Cryptosporidiosis, H2 2014 7
Number of Products under Development for Cryptosporidiosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Cryptosporidiosis - Pipeline by ioGenetics, LLC, H2 2014 14
Assessment by Monotherapy Products, H2 2014 15
Number of Products by Stage and Target, H2 2014 17
Number of Products by Stage and Mechanism of Action, H2 2014 19
Number of Products by Stage and Route of Administration, H2 2014 20
Number of Products by Stage and Molecule Type, H2 2014 22
Cryptosporidiosis - Dormant Projects, H2 2014 30

List of Figures

Number of Products under Development for Cryptosporidiosis, H2 2014 7
Number of Products under Development for Cryptosporidiosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 15
Number of Products by Top 10 Targets, H2 2014 16
Number of Products by Stage and Top 10 Targets, H2 2014 16
Number of Products by Top 10 Mechanism of Actions, H2 2014 18
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 18
Number of Products by Top 10 Molecule Types, H2 2014 21
Number of Products by Stage and Top 10 Molecule Types, H2 2014 21

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing